ascopubs.org

Phase I and Pharmacokinetic Study of the Novel MDR1 and MRP1 Inhibitor Biricodar Administered Alone and in Combination With Doxorubicin

PURPOSE: To evaluate the safety, tolerability, and pharmacokinetics of biricodar (VX-710), an inhibitor of P-glycoprotein (P-gp) and multidrug resistance–associated protein (MRP1), alone and with ...
ascopubs.org

Phase I and Pharmacokinetic Study of the Oral Farnesyl Transferase Inhibitor SCH 66336 Given Twice Daily to Patients With Advanced Solid Tumors

Abstract PURPOSE: A single-agent dose-escalating phase I and pharmacokinetic study on the farnesyl transferase inhibitor SCH 66336 was performed to determine the safety profile, maximum-tolerated dose ...
Nasdaq

Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an ...
Morningstar

Epirium Bio Presented Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data for MF-300, Supporting its Role in Muscle Health, as a Late-Breaker at the ...

Epirium Bio Presented Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data for MF-300, Supporting its Role in Muscle Health, as a Late-Breaker at the Gerontological Society of America ...
Seeking Alpha

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET ...

No quantifiable VYN201 plasma concentrations above the assay lower limit of quantification supports “soft” drug approach for topical pan-BD BET inhibitor All hematological parameters, including ...
Nasdaq

Adial Pharmaceuticals Completes Pharmacokinetics Study of AD04, Prepares for FDA End-of-Phase 2 Interaction

Adial Pharmaceuticals has completed a pharmacokinetics study of its investigational drug AD04, aimed at treating Alcohol Use Disorder (AUD) in patients with a specific genomic biomarker. The results ...